Dapagliflozin 10mg Tab

ApprovedRecruiting
1 views this week 0 watching Active
Interest: 50/100
50
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Heart Failure

Conditions

Heart Failure

Trial Timeline

Nov 8, 2023 → Mar 1, 2026

About Dapagliflozin 10mg Tab

Dapagliflozin 10mg Tab is a approved stage product being developed by AstraZeneca for Heart Failure. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05741658. Target conditions include Heart Failure.

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure were approved

Approved (20) Terminated (3) Active (0)
ConivaptanAstellas PharmaApproved
RegadenosonAstellas PharmaApproved
Regadenoson + GadoliniumAstellas PharmaApproved
regadenosonAstellas PharmaApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05741658ApprovedRecruiting
NCT04794517Phase 2Completed

Competing Products

20 competing products in Heart Failure

See all competitors
ProductCompanyStageHype Score
mRNA-0184ModernaPhase 1
0
IV diureticNuwellisPre-clinical
16
IV Loop DiureticsNuwellisPre-clinical
23
Stepped pharmacologic careNuwellisPhase 3
30
IV Loop Diuretics (LD)NuwellisPre-clinical
8
TRV120027 + Normal SalineTrevenaPhase 1
19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
TRV120027 + PlaceboTrevenaPhase 1/2
22
Ilofotase alfa + PlaceboAM-PharmaPhase 2
25
INXN-4001PrecigenPhase 1
23
LY3461767 + PlaceboEli LillyPhase 1
29
SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
43
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetilDaiichi SankyoPhase 3
32
OlmesartanDaiichi SankyoPhase 3
40
Carperitide + PlaceboDaiichi SankyoPhase 2
35
EdoxabanDaiichi SankyoPre-clinical
22
RegadenosonAstellas PharmaPhase 1
29
Advagraf + PrografAstellas PharmaPhase 2
35